Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + azacitidine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Chidamide + azacitidine is a combination epigenetic therapy that pairs a histone deacetylase inhibitor (chidamide) with a DNA methyltransferase inhibitor (azacitidine). This dual epigenetic regulating treatment shows synergistic effects in treating hematological malignancies. Chidamide specifically targets HDAC1, 2, 3, and 10, preventing histone deacetylation and promoting gene expression. Azacitidine works through cytotoxicity (incorporating into RNA/DNA) and hypomethylation (inhibiting DNA methyltransferase). The combination has shown particular efficacy in peripheral T-cell lymphomas, especially angioimmunoblastic T-cell lymphoma (AITL), and is being investigated for acute myeloid leukemia and other hematological cancers.
- Brand names
- Vidaza (azacitidine)Onureg (azacitidine)Epidaza (chidamide)
- Other names
- 5-azacytidine (azacitidine)HBI-8000 (chidamide)
02
Targets
HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on chidamide + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + azacitidine.